R&D News | pharmaphorum

News

Job losses loom at Achilles as TIL therapy platform is cut

Employees at Achilles Therapeutics are bracing themselves for job losses after the UK biotech announced that it is dropping its R&D in tumour-infiltrating lymphocyte (TIL) therapies for

News

Respiratory biotech Upstream joins Nasdaq IPO surge

Upstream Bio has become the latest biotech to chance its arm with a public listing in the US, hoping to raise funds for inflammatory respiratory disease therapy verekitug.

News

After FDA no, MSD/Daiichi post new data with lung cancer ADC

MSD and Daiichi Sankyo's patritumab deruxtecan hit its main objective in a phase 3 lung cancer study that reinforces its potential as a new treatment option for patients after first-line tr

News

Tobacco firm PMI divests Vectura at a loss after backlash

Philip Morris International (PMI) is selling inhaled drug specialist Vectura to Molex Asia Holdings for a fraction of the £1.1 billion ($1.45 billion) it paid for the business three years a

News

Trial sets up filings for Boehringer IPF drug nerandomilast

With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy O

News

ESMO: Pfizer drug helps cancer patients gain weight

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no a

Job losses loom at Achilles as TIL therapy platform is cut

Respiratory biotech Upstream joins Nasdaq IPO surge

After FDA no, MSD/Daiichi post new data with lung cancer ADC

Tobacco firm PMI divests Vectura at a loss after backlash

Trial sets up filings for Boehringer IPF drug nerandomilast

ESMO: Pfizer drug helps cancer patients gain weight

Euro VCs team up to invigorate life sciences ecosystem

How to meet your physicians where they are online

News

Editor's Picks